Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
3SBio Inc. Obtains SFDA Approval To Join Global Phase III Trial For Voclosporin
3SBio Inc. announced that the State Food and Drug Administration (SFDA) has approved 3SBio's application to conduct the China arm of the multi-center phase III trial of voclosporin, a new generation calcineurin inhibitor licensed from Isotechnika Pharma Inc. According to the approved protocol, this will be a phase III, randomized, multi-center, concentration-controlled comparison study on renal transplant patients. Patient enrollment is expected to begin in the third quarter of 2012.
Latest Developments for 3SBio Inc
- 3SBio Inc Enters Into Merger Agreement For Going Private Transaction
- 3SBio Inc Reiterates FY 2012 Revenue Guidance
- 3SBio Inc's Independent Committee Selects Legal Counsel in connection with Going Private Proposal
- 3SBio Inc Announces Receipt Of Going Private Proposal At $15 Per American Depositary Share
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters